[go: up one dir, main page]

PE20200338A1 - Composiciones cannabinoides novedosas y metodos para tratar la epilepsia infantil - Google Patents

Composiciones cannabinoides novedosas y metodos para tratar la epilepsia infantil

Info

Publication number
PE20200338A1
PE20200338A1 PE2019001299A PE2019001299A PE20200338A1 PE 20200338 A1 PE20200338 A1 PE 20200338A1 PE 2019001299 A PE2019001299 A PE 2019001299A PE 2019001299 A PE2019001299 A PE 2019001299A PE 20200338 A1 PE20200338 A1 PE 20200338A1
Authority
PE
Peru
Prior art keywords
methods
childhood epilepsy
cannabinoid compositions
novel cannabinoid
treat childhood
Prior art date
Application number
PE2019001299A
Other languages
English (en)
Inventor
Catherine Jacobson
Caleb Joshua Eades
Original Assignee
Tilray Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tilray Inc filed Critical Tilray Inc
Publication of PE20200338A1 publication Critical patent/PE20200338A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pyrane Compounds (AREA)

Abstract

Referido a una composicion farmaceutica que comprende cannabidiol (CBD) y delta-9-tetrahidrocannabinol (THC) en una relacion de alrededor de 40:1 a alrededor de 60:1; y su uso en el tratamiento de la epilepsia infantil.
PE2019001299A 2016-12-20 2017-12-20 Composiciones cannabinoides novedosas y metodos para tratar la epilepsia infantil PE20200338A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662436861P 2016-12-20 2016-12-20
PCT/IB2017/001683 WO2018115962A1 (en) 2016-12-20 2017-12-20 Novel cannabinoid compositions and methods of treating pediatric epilepsy

Publications (1)

Publication Number Publication Date
PE20200338A1 true PE20200338A1 (es) 2020-02-14

Family

ID=61028091

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019001299A PE20200338A1 (es) 2016-12-20 2017-12-20 Composiciones cannabinoides novedosas y metodos para tratar la epilepsia infantil

Country Status (12)

Country Link
US (1) US20200215022A1 (es)
EP (1) EP3558297A1 (es)
JP (2) JP2020514282A (es)
KR (1) KR20190099221A (es)
AU (1) AU2017381587A1 (es)
BR (1) BR112019012776A2 (es)
CA (1) CA3046320A1 (es)
CL (1) CL2019001668A1 (es)
CO (1) CO2019006911A2 (es)
MX (1) MX2019007496A (es)
PE (1) PE20200338A1 (es)
WO (1) WO2018115962A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
IL261132A (en) * 2018-08-13 2018-11-04 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Formulated cannabis oil powder by nanoemulsifycation, methods of producing and uses thereof
GB2580653A (en) * 2019-01-21 2020-07-29 Gw Res Ltd Use of cannabinoids in the treatment of comorbidities associated with epilepsy
CA3130763A1 (en) 2019-02-25 2020-09-03 Ginkgo Bioworks, Inc. Biosynthesis of cannabinoids and cannabinoid precursors
US11759447B1 (en) 2019-06-26 2023-09-19 RCR BioPharma Compound and method for treating diseases and disorders
GB2598922A (en) 2020-09-18 2022-03-23 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
WO2022232574A1 (en) 2021-04-29 2022-11-03 Tilray, Inc. Cannabidiol-dominant formulations, methods of manufacturing, and uses thereof
WO2023047308A1 (en) * 2021-09-22 2023-03-30 Avicanna Inc. Methods for reducing or eliminating incidence of seizures and sudden unexpected death in epilepsy
US12036228B2 (en) 2022-04-12 2024-07-16 Shackelford Pharma Inc. Treatment of seizure disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002231970B2 (en) * 2001-02-14 2007-08-16 Jazz Pharmaceuticals Research Uk Limited Mucoadhesive pharmaceutical formulations
GB2530001B (en) * 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2531282A (en) * 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
EA201791299A1 (ru) * 2014-12-12 2017-12-29 ОХАЙ ЭНЕРДЖЕТИКС ПиБиСи Микроинкапсулированные композиции каннабиноидов
JP2018507262A (ja) * 2015-03-02 2018-03-15 アフギン ファーマ, エルエルシーAfgin Pharma, Llc カンナビノイドを用いた、局所局部的神経作用療法
CA2981772C (en) * 2016-02-11 2018-12-18 Gelpell Ag Oral solid cannabinoid formulations, methods for producing and using thereof

Also Published As

Publication number Publication date
JP2023001138A (ja) 2023-01-04
CO2019006911A2 (es) 2019-08-30
CA3046320A1 (en) 2018-06-28
MX2019007496A (es) 2019-10-30
KR20190099221A (ko) 2019-08-26
AU2017381587A1 (en) 2019-06-20
JP2020514282A (ja) 2020-05-21
BR112019012776A2 (pt) 2019-12-10
WO2018115962A1 (en) 2018-06-28
CL2019001668A1 (es) 2019-09-06
EP3558297A1 (en) 2019-10-30
US20200215022A1 (en) 2020-07-09

Similar Documents

Publication Publication Date Title
PE20200338A1 (es) Composiciones cannabinoides novedosas y metodos para tratar la epilepsia infantil
CL2020000632A1 (es) Composición y método para el tratamiento del autismo.
MX2021008702A (es) Uso de cannabinoides en el tratamiento de las comorbilidades asociadas a la epilepsia.
MX2018016078A (es) Composiciones que comprenden cepas bacterianas.
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
MX2019008337A (es) Uso de cannabinoides para el tratamiento de epilepsia.
CO2021001061A2 (es) Composición y método para tratar el dolor
DOP2015000058A (es) Derivados tricíclicos de quinolinas y de quinoxalinas
MX2018002990A (es) Uso de la akkermansia pasteurizada para tratar trastornos metabolicos.
MX2017015083A (es) Composiciones cosmeticas que comprenden e/z-bencilideno-5,6-dimeto xi-3,3-dimetilindan-1-ona.
PE20200726A1 (es) Composicion de cannabis
DOP2015000246A (es) Derivados de oxopiridina sustituida y usos de los mismos en el tratamiento de trastornos cardiovasculares
CL2017001893A1 (es) Uso de prg4 como agente antiinflamatorio
CL2015002677A1 (es) Composiciones que comprenden selenio y uso de las mismas para el tratamiento y prevención de enfermedades o condiciones asociadas con la disfunción mitocondrial.
MX2015009105A (es) Composiciones en solucion solida y su uso en inflamacion cronica.
MX2018013240A (es) Composiciones antiirritantes sinergisticas de taurina y aloe.
UY36224A (es) Compuestos tricíclicos de imidazo-pirimidinona
MX378687B (es) Formulacion de vitamina soluble en grasa.
CL2011002675A1 (es) Uso de compuestos derivados de nitrato o sulfato de 9-purin-9-il-3,4-dihidroxitetrahidrofuran-2-il-metilo para reducir la presion intraocular ; composicion farmaceutica oftalmica que comprende los compuestos; y formulacion oftalmica de uso topico que los comprende.
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
CL2015000039A1 (es) Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis.
MX2015014713A (es) Uso de una composicion que comprende aceite de pescado y jugo para el tratamiento y/o postratamiento de cancer.
DOP2016000007A (es) Pirazolpiridinas sustituidas
MX2015011255A (es) Composicion a base de flavonoides para uso farmaceutico, nutricional o cosmetico que tiene accion antioxidante potenciada.
DOP2016000118A (es) Tienopirimidinas como inhibidores mknk1 y mknk2